Role of gut-derived protein-bound uremic toxins in cardiorenal syndrome and potential treatment modalities

Circulation Journal

Volumn 79, Issue 10, 2015, Pages 2088-2097

  Lekawanvijit, Suree ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

Author keywords

Cardiorenal syndrome; Gut derived PBUTs; Indoxyl sulfate; P cresyl sulfate; Protein bound uremic toxins (PBUTs)

Indexed keywords

INDICAN; PROTEIN BOUND UREMIC TOXIN; UNCLASSIFIED DRUG; UREMIC TOXIN; BACTERIAL TOXIN;

ARTICLE; CARDIORENAL SYNDROME; HEMODIALYSIS; HEMOSTASIS; HUMAN; KIDNEY DISEASE; METABOLIC REGULATION; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PROTEIN BINDING; RISK FACTOR; ANIMAL; COLON; INTESTINE FLORA; METABOLISM; MICROBIOLOGY;

ANIMALS; BACTERIAL TOXINS; CARDIO-RENAL SYNDROME; COLON; GASTROINTESTINAL MICROBIOME; HUMANS;

EID: 84942540625     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-15-0749     Document Type: Article

References (129)

1. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005; 20: 1048-1056
2. Elsayed EF, Tighiouart H, Griffith J, Kurth T, Levey AS, Salem D, et al. Cardiovascular disease and subsequent kidney disease. Arch Intern Med 2007; 167: 1130-1136
3. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-210
4. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426
5. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardio-vascular outcomes after myocardial infarction. N Engl J Med 2004; 351: 1285-1295
6. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32: S112-S119
7. United States Renal Data System. 2014 USRDS annual data report: An overview of the epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2014
8. Hoerger TJ, Simpson SA, Yarnoff BO, Pavkov ME, Rios Burrows N, Saydah SH, et al. The future burden of CKD in the United States: A simulation model for the CDC CKD Initiative. Am J Kidney Dis 2015; 65: 403-411
9. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108: 2154-2169
10. Barrett BJ, Parfrey PS, Morgan J, Barre P, Fine A, Goldstein MB, et al. Prediction of early death in end-stage renal disease patients starting dialysis. Am J Kidney Dis 1997; 29: 214-222
11. Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 2009; 4(Suppl 1): S79-S91
12. Amann K, Neususs R, Ritz E, Irzyniec T, Wiest G, Mall G. Changes of vascular architecture independent of blood pressure in experimental uremia. Am J Hypertens 1995; 8: 409-417
13. Rostand SG, Kirk KA, Rutsky EA. Dialysis-associated ischemic heart disease: Insights from coronary angiography. Kidney Int 1984; 25: 653-659
14. London GM, Pannier B, Guerin AP, Blacher J, Marchais SJ, Darne B, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: Follow-up of an interventional study. J Am Soc Nephrol 2001; 12: 2759-2767
15. Gross ML, Ritz E. Hypertrophy and fibrosis in the cardiomyopathy of uremia: Beyond coronary heart disease. Semin Dial 2008; 21: 308-318
16. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, et al. Review on uremic toxins: Cassification, concentration, and interindividual variability. Kidney Int 2003; 63: 1934-1943
17. Meert N, Schepers E, De Smet R, Argiles A, Cohen G, Deppisch R, et al. Inconsistency of reported uremic toxin concentrations. Artif Organs 2007; 31: 600-611
18. Duranton F, Cohen G, De Smet R, Rodriguez M, Jankowski J, Vanholder R, et al. Normal and pathologic concentrations of uremic toxins. J Am Soc Nephrol 2012; 23: 1258-1270
19. Aronov PA, Luo FJ, Plummer NS, Quan Z, Holmes S, Hostetter TH, et al. Colonic contribution to uremic solutes. J Am Soc Nephrol 2011; 22: 1769-1776
20. Atoh K, Itoh H, Haneda M. Serum indoxyl sulfate levels in patients with diabetic nephropathy: Relation to renal function. Diabetes Res Clin Pract 2009; 83: 220-226
21. Wu IW, Hsu KH, Hsu HJ, Lee CC, Sun CY, Tsai CJ, et al. Serum free p-cresyl sulfate levels predict cardiovascular and all-cause mortality in elderly hemodialysis patients: A prospective cohort study. Nephrol Dial Transplant 2012; 27: 1169-1175
22. De Smet R, Van Kaer J, Van Vlem B, De Cubber A, Brunet P, Lameire N, et al. Toxicity of free p-cresol: A prospective and crosssectional analysis. Clin Chem 2003; 49: 470-478
23. Devine E, Krieter DH, Ruth M, Jankovski J, Lemke HD. Binding affinity and capacity for the uremic toxin indoxyl sulfate. Toxins (Basel) 2014; 6: 416-429
24. Uchikawa T, Shimano M, Inden Y, Murohara T. Serum albumin levels predict clinical outcomes in chronic kidney disease (CKD) patients undergoing cardiac resynchronization therapy. Intern Med 2014; 53: 555-561
25. de Loor H, Bammens B, Evenepoel P, De Preter V, Verbeke K. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005; 51: 1535-1538
26. Liabeuf S, Drueke TB, Massy ZA. Protein-bound uremic toxins: New insight from clinical studies. Toxins (Basel) 2011; 3: 911-919
27. Lekawanvijit S, Kompa AR, Wang BH, Kelly DJ, Krum H. Cardiorenal syndrome: The emerging role of protein-bound uremic toxins. Circ Res 2012; 111: 1470-1483
28. Yoshikawa D, Ishii H, Suzuki S, Takeshita K, Kumagai S, Hayashi M, et al. Plasma indoxyl sulfate and estimated glomerular filtrationrate. Circ J 2014; 78: 2477-2482
29. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009; 4: 1551-1558
30. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, Tsai CJ, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 2011; 26: 938-947
31. Liabeuf S, Barreto DV, Barreto FC, Meert N, Glorieux G, Schepers E, et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010; 25: 1183-1191
32. Shimizu H, Bolati D, Adijiang A, Adelibieke Y, Muteliefu G, Enomoto A, et al. Indoxyl sulfate downregulates renal expression of Klotho through production of ROS and activation of nuclear factor-kB. Am J Nephrol 2011; 33: 319-324
33. Sun CY, Chang SC, Wu MS. Uremic toxins induce kidney fibrosis by activating intrarenal renin-angiotensin-aldosterone system associated epithelial-to-mesenchymal transition. PLoS One 2012; 7: e34026, doi:10.1371/journal.pone.0034026
34. Sun CY, Chang SC, Wu MS. Suppression of Klotho expression by protein-bound uremic toxins is associated with increased DNA methyltransferase expression and DNA hypermethylation. Kidney Int 2012; 81: 640-650
35. Ichii O, Otsuka-Kanazawa S, Nakamura T, Ueno M, Kon Y, Chen W, et al. Podocyte injury caused by indoxyl sulfate, a uremic toxin and aryl-hydrocarbon receptor ligand. PLoS One 2014; 9: e108448, doi:10.1371/journal.pone.0108448
36. Meijers BK, Van Kerckhoven S, Verbeke K, Dehaen W, Vanrenterghem Y, Hoylaerts MF, et al. The uremic retention solute p-cresyl sulfate and markers of endothelial damage. Am J Kidney Dis 2009; 54: 891-901
37. Masai N, Tatebe J, Yoshino G, Morita T. Indoxyl sulfate stimulates monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells by inducing oxidative stress through activation of the NADPH oxidase-nuclear factor-kappaB pathway. Circ J 2010; 74: 2216-2224
38. Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, Vanholder R. P-cresylsulphate, the main in vitro metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007; 22: 592-596
39. Yamamoto H, Tsuruoka S, Ioka T, Ando H, Ito C, Akimoto T, et al. Indoxyl sulfate stimulates proliferation of rat vascular smooth muscle cells. Kidney Int 2006; 69: 1780-1785
40. Adelibieke Y, Yisireyili M, Ng HY, Saito S, Nishijima F, Niwa T. Indoxyl sulfate induces IL-6 expression in vascular endothelial and smooth muscle cells through OAT3-mediated uptake and activation of AhR/NF-kappaB pathway. Nephron Exp Nephrol 2014; 128: 1-8
41. Watanabe I, Tatebe J, Namba S, Koizumi M, Yamazaki J, Morita T. Activation of aryl hydrocarbon receptor mediates indoxyl sulfate- induced monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells. Circ J 2013; 77: 224-230
42. Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am J Nephrol 2007; 27: 30-35
43. Sato B, Yoshikawa D, Ishii H, Kikuchi R, Arima T, Takeshita K, et al. Indoxyl sulfate, a uremic toxin, and carotid intima-media thickness in patients with coronary artery disease. Int J Cardiol 2013; 163: 214-216
44. Adijiang A, Higuchi Y, Nishijima F, Shimizu H, Niwa T. Indoxyl sulfate, a uremic toxin, promotes cell senescence in aorta of hypertensive rats. Biochem Biophys Res Commun 2010; 399: 637-641
45. Muteliefu G, Enomoto A, Jiang P, Takahashi M, Niwa T. Indoxyl sulphate induces oxidative stress and the expression of osteoblastspecific proteins in vascular smooth muscle cells. Nephrol Dial Transplant 2009; 24: 2051-2058
46. Lekawanvijit S, Adrahtas A, Kelly DJ, Kompa AR, Wang BH, Krum H. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J 2010; 31: 1771-1779
47. Lekawanvijit S, Kompa AR, Manabe M, Wang BH, Langham RG, Nishijima F, et al. Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sulfate. PLoS One 2012; 7: e41281, doi: 10.1371/journal.pone.0041281
48. Fujii H, Nishijima F, Goto S, Sugano M, Yamato H, Kitazawa R, et al. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant 2009; 24: 2089-2095
49. Liu S, Wang BH, Kompa AR, Lekawanvijit S, Krum H. Antagonistsof organic anion transporters 1 and 3 ameliorate adverse cardiac remodelling induced by uremic toxin indoxyl sulfate. Int J Cardiol 2012; 158: 457-458
50. Chen WT, Chen YC, Hsieh MH, Huang SY, Kao YH, Chen YA, et al. The uremic toxin indoxyl sulfate increases pulmonary vein and atrial arrhythmogenesis. J Cardiovasc Electrophysiol 2015; 26: 203-210
51. Shimazu S, Hirashiki A, Okumura T, Yamada T, Okamoto R, Shinoda N, et al. Association between indoxyl sulfate and cardiac dysfunction and prognosis in patients with dilated cardiomyopathy. Circ J 2013; 77: 390-396
52. Dou L, Bertrand E, Cerini C, Faure V, Sampol J, Vanholder R, et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004; 65: 442-451
53. Dou L, Jourde-Chiche N, Faure V, Cerini C, Berland Y, Dignat- George F, et al. The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells. J Thromb Haemost 2007; 5: 1302-1308
54. Yu M, Kim YJ, Kang DH. Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress. Clin J Am Soc Nephrol 2011; 6: 30-39
55. Pletinck A, Glorieux G, Schepers E, Cohen G, Gondouin B, Van Landschoot M, et al. Protein-bound uremic toxins stimulate crosstalk between leukocytes and vessel wall. J Am Soc Nephrol 2013; 24: 1981-1994
56. Niwa T, Ise M. Indoxyl sulfate, a circulating uremic toxin, stimulates the progression of glomerular sclerosis. J Lab Clin Med 1994; 124: 96-104
57. Miyazaki T, Ise M, Seo H, Niwa T. Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1 and pro-alpha 1(I) collagen in uremic rat kidneys. Kidney Int Suppl 1997; 62: S15-S22
58. Miyazaki T, Aoyama I, Ise M, Seo H, Niwa T. An oral sorbent reduces overload of indoxyl sulphate and gene expression of TGFbeta1 in uraemic rat kidneys. Nephrol Dial Transplant 2000; 15: 1773-1781
59. Sun CY, Hsu HH, Wu MS. p-Cresol sulfate and indoxyl sulfate induce similar cellular inflammatory gene expressions in cultured proximal renal tubular cells. Nephrol Dial Transplant 2012; 28: 70-78
60. Niwa T, Ise M, Miyazaki T. Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate. Am J Nephrol 1994; 14: 207-212
61. Tamada S, Asai T, Kuwabara N, Iwai T, Uchida J, Teramoto K, et al. Molecular mechanisms and therapeutic strategies of chronic renal injury: The role of nuclear factor kappaB activation in the development of renal fibrosis. J Pharmacol Sci 2006; 100: 17-21
62. Gelasco AK, Raymond JR. Indoxyl sulfate induces complex redox alterations in mesangial cells. Am J Physiol Renal Physiol 2006; 290: F1551-F1558
63. Motojima M, Hosokawa A, Yamato H, Muraki T, Yoshioka T. Uremic toxins of organic anions up-regulate PAI-1 expression by induction of NF-kappaB and free radical in proximal tubular cells. Kidney Int 2003; 63: 1671-1680
64. Tumur Z, Niwa T. Oral sorbent AST-120 increases renal NO synthesis in uremic rats. J Ren Nutr 2008; 18: 60-64
65. Owada S, Goto S, Bannai K, Hayashi H, Nishijima F, Niwa T. Indoxyl sulfate reduces superoxide scavenging activity in the kidneys of normal and uremic rats. Am J Nephrol 2008; 28: 446-454
66. Neirynck N, Vanholder R, Schepers E, Eloot S, Pletinck A, Glorieux G. An update on uremic toxins. Int Urol Nephrol 2012; 45: 139-150
67. Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K, et al. p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 2010; 5: 1182-1189
68. Bammens B, Evenepoel P, Keuleers H, Verbeke K, Vanrenterghem Y. Free serum concentrations of the protein-bound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006; 69: 1081-1087
69. Peng YS, Ding HC, Lin YT, Syu JP, Chen Y, Wang SM. Uremic toxin p-cresol induces disassembly of gap junctions of cardiomyocytes. Toxicology 2012; 302: 11-17
70. Dou L, Cerini C, Brunet P, Guilianelli C, Moal V, Grau G, et al. P-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney Int 2002; 62: 1999-2009
71. Sanders JM, Bucher JR, Peckham JC, Kissling GE, Hejtmancik MR, Chhabra RS. Carcinogenesis studies of cresols in rats and mice. Toxicology 2009; 257: 33-39
72. Wu ZF, Liu GL, Zhou Z, Wang GX, Xia L, Liu JL. Induction of immune-related gene expression in Ctenopharyngodon idella kidney cells by secondary metabolites from immunostimulatory Alcaligenes faecalis FY-3. Scand J Immunol 2012; 76: 131-140
73. Jourde-Chiche N, Dou L, Sabatier F, Calaf R, Cerini C, Robert S, et al. Levels of circulating endothelial progenitor cells are related to uremic toxins and vascular injury in hemodialysis patients. J Thromb Haemost 2009; 7: 1576-1584
74. Satoh M, Hayashi H, Watanabe M, Ueda K, Yamato H, Yoshioka T, et al. Uremic toxins overload accelerates renal damage in a rat model of chronic renal failure. Nephron Exp Nephrol 2003; 95: e111-e118, doi:10.1159/000074327
75. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97: 138-141
76. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 2002; 325: 1202
77. Heinz J, Kropf S, Luley C, Dierkes J. Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: A metaanalysis. Am J Kidney Dis 2009; 54: 478-489
78. Thambyrajah J, Townend JN. Homocysteine and atherothrombosis: Mechanisms for injury. Eur Heart J 2000; 21: 967-974
79. Hofmann MA, Lalla E, Lu Y, Gleason MR, Wolf BM, Tanji N, et al. Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model. J Clin Invest 2001; 107: 675-683
80. Brown JC, Rosenquist TH, Monaghan DT. ERK2 activation by homocysteine in vascular smooth muscle cells. Biochem Biophys Res Commun 1998; 251: 669-676
81. Van Campenhout A, Moran CS, Parr A, Clancy P, Rush C, Jakubowski H, et al. Role of homocysteine in aortic calcification and osteogenic cell differentiation. Atherosclerosis 2009; 202: 557-566
82. Lee JC, Downing SE. Negative inotropic effects of phenol on isolated cardiac muscle. Am J Pathol 1981; 102: 367-372
83. Lekawanvijit S, Krum H. Novel combination therapy to target heart and kidney. In: Goldsmith D, Covic A, Spaak J, editors. Cardiorenal clinical challenges. Heidelberg: Springer, 2015; 197-208
84. Marzocco S, Dal Piaz F, Di Micco L, Torraca S, Sirico ML, Tartaglia D, et al. Very low protein diet reduces indoxyl sulfate levels in chronic kidney disease. Blood Purif 2013; 35: 196-201
85. Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P. Evidence for impaired assimilation of protein in chronic renal failure. Kidney Int 2003; 64: 2196-2203
86. Wu MJ, Chang CS, Cheng CH, Chen CH, Lee WC, Hsu YH, et al. Colonic transit time in long-term dialysis patients. Am J Kidney Dis 2004; 44: 322-327
87. Hida M, Aiba Y, Sawamura S, Suzuki N, Satoh T, Koga Y. Inhibition of the accumulation of uremic toxins in the blood and their precursors in the feces after oral administration of Lebenin, a lactic acid bacteria preparation, to uremic patients undergoing hemodialysis. Nephron 1996; 74: 349-355
88. Takayama F, Taki K, Niwa T. Bifidobacterium in gastro-resistant seamless capsule reduces serum levels of indoxyl sulfate in patients on hemodialysis. Am J Kidney Dis 2003; 41: S142-S145
89. Ranganathan N, Ranganathan P, Friedman EA, Joseph A, Delano B, Goldfarb DS, et al. Pilot study of probiotic dietary supplementation for promoting healthy kidney function in patients with chronic kidney disease. Adv Ther 2010; 27: 634-647
90. Furuse SU, Ohse T, Jo-Watanabe A, Shigehisa A, Kawakami K, Matsuki T, et al. Galacto-oligosaccharides attenuate renal injury with microbiota modification. Physiol Rep 2014; 2: e12029, doi:10.14814/phy2.12029
91. Meijers BK, De Preter V, Verbeke K, Vanrenterghem Y, Evenepoel P. p-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant 2010; 25: 219-224
92. Nakabayashi I, Nakamura M, Kawakami K, Ohta T, Kato I, Uchida K, et al. Effects of synbiotic treatment on serum level of p-cresol in haemodialysis patients: A preliminary study. Nephrol Dial Transplant 2011; 26: 1094-1098
93. Guida B, Germano R, Trio R, Russo D, Memoli B, Grumetto L, et al. Effect of short-term synbiotic treatment on plasma p-cresol levels in patients with chronic renal failure: A randomized clinical trial. Nutr Metab Cardiovasc Dis 2014; 24: 1043-1049
94. Mishima E, Fukuda S, Shima H, Hirayama A, Akiyama Y, Takeuchi Y, et al. Alteration of the intestinal environment by lubiprostone is associated with amelioration of adenine-induced CKD. J Am Soc Nephrol 2015; 26: 1787-1794
95. Shen B, Pardi DS, Bennett AE, Queener E, Kammer P, Hammel JP, et al. The efficacy and tolerability of AST-120 (spherical carbon adsorbent) in active pouchitis. Am J Gastroenterol 2009; 104: 1468-1474
96. Aoyama I, Shimokata K, Niwa T. An oral adsorbent downregulates renal expression of genes that promote interstitial inflammation and fibrosis in diabetic rats. Nephron 2002; 92: 635-651
97. Nakagawa N, Hasebe N, Sumitomo K, Fujino T, Fukuzawa J, Hirayama T, et al. An oral adsorbent, AST-120, suppresses oxidative stress in uremic rats. Am J Nephrol 2006; 26: 455-461
98. Yamamoto S, Zuo Y, Ma J, Yancey PG, Hunley TE, Motojima M, et al. Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice. Nephrol Dial Transplant 2011; 26: 2491-2497
99. Sato T, Liang K, Vaziri ND. Protein restriction and AST-120 improve lipoprotein lipase and VLDL receptor in focal glomerulosclerosis. Kidney Int 2003; 64: 1780-1786
100. Shimizu H, Bolati D, Adijiang A, Muteliefu G, Enomoto A, Nishijima F, et al. NF-kappaB plays an important role in indoxyl sulfate-induced cellular senescence, fibrotic gene expression, and inhibition of proliferation in proximal tubular cells. Am J Physiol Cell Physiol 2011; 301: C1201-C1212
101. Maeda K, Hamada C, Hayashi T, Shou I, Wakabayashi M, Fukui M, et al. Long-term effects of the oral adsorbent, AST-120, in patients with chronic renal failure. J Int Med Res 2009; 37: 205-213
102. Ueda H, Shibahara N, Takagi S, Inoue T, Katsuoka Y. AST-120, an oral adsorbent, delays the initiation of dialysis in patients with chronic kidney diseases. Ther Apher Dial 2007; 11: 189-195
103. Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: An oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int Suppl 1997; 62: S23-S28
104. Iida S, Kohno K, Yoshimura J, Ueda S, Usui M, Miyazaki H, et al. Carbonic-adsorbent AST-120 reduces overload of indoxyl sulfate and the plasma level of TGF-beta1 in patients with chronic renal failure. Clin Exp Nephrol 2006; 10: 262-267
105. Sanaka T, Akizawa T, Koide K, Koshikawa S. Protective effect of an oral adsorbent on renal function in chronic renal failure: Determinants of its efficacy in diabetic nephropathy. Ther Apher Dial 2004; 8: 232-240
106. Hayashino Y, Fukuhara S, Akizawa T, Asano Y, Wakita T, Onishi Y, et al. Cost-effectiveness of administering oral adsorbent AST- 120 to patients with diabetes and advance-stage chronic kidney disease. Diabetes Res Clin Pract 2010; 90: 154-159
107. Ueda H, Shibahara N, Takagi S, Inoue T, Katsuoka Y. AST-120 treatment in pre-dialysis period affects the prognosis in patients on hemodialysis. Ren Fail 2008; 30: 856-860
108. Nakamura T, Kawagoe Y, Matsuda T, Ueda Y, Shimada N, Ebihara I, et al. Oral ADSORBENT AST-120 decreases carotid intimamedia thickness and arterial stiffness in patients with chronic renal failure. Kidney Blood Press Res 2004; 27: 121-126
109. Goto S, Kitamura K, Kono K, Nakai K, Fujii H, Nishi S. Association between AST-120 and abdominal aortic calcification in predialysis patients with chronic kidney disease. Clin Exp Nephrol 2013; 17: 365-371
110. Nakai K, Fujii H, Kono K, Goto S, Fukagawa M, Nishi S. Effects of AST-120 on left ventricular mass in predialysis patients. Am J Nephrol 2011; 33: 218-223
111. Tsubakihara Y, Takabatake Y, Oka K, Shoji T, Togawa M, Okada N, et al. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients. Am J Kidney Dis 2003; 41: S38-S41
112. Owada A, Nakao M, Koike J, Ujiie K, Tomita K, Shiigai T. Effects of oral adsorbent AST-120 on the progression of chronic renal failure: A randomized controlled study. Kidney Int Suppl 1997; 63: S188-S190
113. Sanaka T, Fujimoto K, Niwayama J, Nishimura H, Naito T, Higuchi C, et al. Effect of combined treatment of oral sorbent with proteinrestricted diet on change of reciprocal creatinine slope in patients with CRF. Am J Kidney Dis 2003; 41: S35-S37
114. Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, et al. Effect of a carbonaceous oral adsorbent on the progression of CKD: A multicenter, randomized, controlled trial. Am J Kidney Dis 2009; 54: 459-467
115. Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Arita K, et al. Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD. J Am Soc Nephrol 2014; 26: 1732-1746
116. Shibahara H, Shibahara N. Cardiorenal protective effect of the oral uremic toxin absorbent AST-120 in chronic heart disease patients with moderate CKD. J Nephrol 2010; 23: 535-540
117. Lekawanvijit S, Kumfu S, Wang BH, Manabe M, Nishijima F, Kelly DJ, et al. The uremic toxin adsorbent AST-120 abrogates cardiorenal injury following myocardial infarction. PLoS One 2013; 8: e83687, doi:10.1371/journal.pone.0083687
118. Rana I, Kompa AR, Skommer J, Wang BH, Lekawanvijit S, Kelly DJ, et al. Contribution of microRNA to pathological fibrosis in cardio-renal syndrome: Impact of uremic toxins. Physiol Rep 2015; 3: e12371, doi:10.14814/phy2.12371
119. Babb AL, Farrell PC, Uvelli DA, Scribner BH. Hemodialyzer evaluation by examination of solute molecular spectra. Trans Am Soc Artif Intern Organs 1972; 18: 98-105, 122
120. Babb AL, Popovich RP, Christopher TG, Scribner BH. The genesis of the square meter-hour hypothesis. Trans Am Soc Artif Intern Organs 1971; 17: 81-91
121. Lesaffer G, De Smet R, Lameire N, Dhondt A, Duym P, Vanholder R. Intradialytic removal of protein-bound uraemic toxins: Role of solute characteristics and of dialyser membrane. Nephrol Dial Transplant 2000; 15: 50-57
122. Meert N, Beerenhout C, Schepers E, Glorieux G, Kooman J, Vanholder R. Evolution of protein-bound uraemic solutes during predilution haemofiltration. J Nephrol 2009; 22: 352-357
123. Meert N, Eloot S, Waterloos MA, Van Landschoot M, Dhondt A, Glorieux G, et al. Effective removal of protein-bound uraemic solutes by different convective strategies: A prospective trial. Nephrol Dial Transplant 2009; 24: 562-570
124. Winchester JF, Silberzweig J, Ronco C, Kuntsevich V, Levine D, Parker T, et al. Sorbents in acute renal failure and end-stage renal disease: Middle molecule and cytokine removal. Blood Purif 2004; 22: 73-77
125. Dinh DC, Recht NS, Hostetter TH, Meyer TW. Coated carbon hemoperfusion provides limited clearance of protein-bound solutes. Artif Organs 2008; 32: 717-724
126. Tijink MS, Wester M, Glorieux G, Gerritsen KG, Sun J, Swart PC, et al. Mixed matrix hollow fiber membranes for removal of proteinbound toxins from human plasma. Biomaterials 2013; 34: 7819-7828
127. Berge-Lefranc D, Chaspoul F, Calaf R, Charpiot P, Brunet P, Gallice P. Binding of p-cresylsulfate and p-cresol to human serum albumin studied by microcalorimetry. J Phys Chem B 2010; 114: 1661-1665
128. United States Renal Data System. 2007 USRDS annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2007
129. Wali RK, Wang GS, Gottlieb SS, Bellumkonda L, Hansalia R, Ramos E, et al. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease. J Am Coll Cardiol 2005; 45: 1051-1060.